MedDataX Logo

Clinical Trial To Evaluate The Effect Of Valsartan On Insulin Sensitivity In Subjects With Impaired Glucose Tolerance

NCT ID: NCT00241072

Last Updated: 2012-05-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

27 participants

Study Classification

INTERVENTIONAL

Study Start Date

2002-09-30

Study Completion Date

2005-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

THE PURPOSE OF THIS STUDY IS TO DETERMINE IF 24 WEEKS OF TREATMENT WITH VALSARTAN (80 MG - 320 MG) IMPROVES INSULIN SENSITIVITY IN SUBJECTS WITH HIGHER THAN NORMAL GLUCOSE LEVELS USING A TEST CALLED THE EUGLYCEMIC CLAMP.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Valsartan on Proteinuria in Patients With Hypertension and Diabetes Mellitus

NCT00241085

PROTEINURIA Hypertension Type 2 Diabetes
COMPLETED PHASE4

To Assess the Effects of Valsartan on Albuminuria/Proteinuria in Hypertensive Patients With Type 2 Diabetes Mellitus

NCT00550095

Microalbuminuria Proteinuria
COMPLETED PHASE4

Comparison Of Morning And Evening Dosing Of Valsartan And Lisinopril In Patients With Diabetes

NCT00241124

Hypertension
COMPLETED PHASE4

A 16 Week Study to Evaluate the Effect on Insulin Sensitivity of Valsartan (320 mg) and Hydrochlorothiazide (25 mg) Combined and Alone, in Patients With Metabolic Syndrome

NCT00170937

METABOLIC SYNDROME HYPERTENSION PRE-HYPERTENSION
COMPLETED PHASE4

Effect of Valsartan on Lipid Subfractions in Hypertensive Patients With Metabolic Syndrome

NCT00394745

Hypertension Metabolic Syndrome
COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension Impaired Glucose Tolerance

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

valsartan

24 WEEKS OF TREATMENT WITH VALSARTAN (80 MG - 320 MG)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

history or presenting hypertension Elevated fasting blood glucose levels -

Exclusion Criteria

Pregnancy potential Diabetes mellitus

Other criteria apply

\-
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Novartis

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Novartis Pharmaceuticals

Role: STUDY_DIRECTOR

Novartis Pharmaceuticals

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CVAL489A2412

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Effect of Valsartan on Carotid Artery Disease
NCT00208767 COMPLETED PHASE2
A Study to Compare Treating Hypertension With Valsartan 160 MG to Valsartan 320 Mg
NCT00241137 COMPLETED PHASE3
Effects of Valsartan and Aliskiren on Hemostatic Indices in Hypertensive Diabetics
NCT01095822 UNKNOWN PHASE4
Efficacy & Safety of Orally Administered Valsartan/Amlodipine Combo Therapy vs Amlodipine Monotherapy in Black Patients With Stage II Hypertension
NCT00353912 COMPLETED PHASE3
To Find Out Whether Valsartan With or Without Other Blood Pressure Medications Would Improve the Ability of the Heart to Fill and Empty, and the Ability of the Heart Muscle to Relax Adequately in People With High Blood Pressure.
NCT00170924 COMPLETED PHASE4
To Compare the Blood Level of Marketed Japanese Valsartan Tablet Formulation vs Global Valsartan Tablet Formulation in Healthy Volunteers
NCT00415883 COMPLETED PHASE1
The DDI Study of SP2086 and Valsartan
NCT02817217 UNKNOWN PHASE1
Antiproteinuric Effect of Valsartan and Lisinopril
NCT00171574 COMPLETED PHASE4
An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Patients With Type II Diabetes
NCT00403481 COMPLETED PHASE4
The VALIDATE Study of Valsartan for Patients With Early Stage Heart Failure
NCT00241098 COMPLETED PHASE4
8 Weeks Study to Evaluate the Efficacy and Safety of Valsartan in Combination With Aliskiren Compared to Valsartan Alone in Patients With Stage 2 Hypertension
NCT00809926 COMPLETED PHASE4
A Study of Valsartan Administered Once Daily Versus Twice Daily, in Patients With Stable, Chronic Heart Failure
NCT00294086 COMPLETED PHASE2
Valsartan Intensified Primary Care Reduction of Blood Pressure Study
NCT00902304 COMPLETED PHASE4
Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus
NCT00927394 COMPLETED PHASE4
Valsartan/Amlodipine As Compared to Losartan Treatment in Stage 2 Systolic Hypertension
NCT00931710 COMPLETED PHASE4
Antialbuminuric Effects of Valsartan and Lisinopril
NCT00171600 TERMINATED PHASE4
The Drug-drug Interaction of SP2086 and Valsartan
NCT02815657 COMPLETED PHASE1
Effectiveness of a Valsartan Based Versus an Amlodipine Based Treatment Strategy in naïve Patients With Stage 1 or Stage 2 Hypertension or in Patients Uncontrolled on Current Monotherapy
NCT00304226 COMPLETED PHASE4
Bioequivalence Study of Valsartan 320mg Tablets Under Fed Conditions
NCT02197494 COMPLETED NA
Assessment of LCZ696 and Valsartan in Asian Patients With Salt-sensitive Hypertension
NCT01681576 COMPLETED PHASE2
Double-dose Valsartan Monotherapy in Hypertension Treatment: an Effectiveness and Safety Evaluation in Chinese Patients.
NCT01541189 COMPLETED PHASE4
A 10-12 Week Study to Evaluate the Safety and Efficacy of 320 mg Valsartan and 80 mg Simvastatin in Combination and as Monotherapies in Treating Hypertension and Hypercholesterolemia
NCT00171093 COMPLETED PHASE3
A Study to Describe Vascular and Renal Effects and Safety of Valsartan in Patients With High Blood Pressure
NCT00171353 COMPLETED PHASE4
Assessment of Renin Inhibition on Insulin Sensitivity, Diastolic Function and Aortic Compliance
NCT01252238 TERMINATED NA
Effectiveness of a Valsartan Based vs an Amlodipine Based Treatment Strategy in naïve Patients With Stage 1 or Stage 2 Hypertension or in Patients Uncontrolled on Current Monotherapy
NCT00351130 COMPLETED PHASE4